ReNeuron Signs License Agreement with Leading US Eye Research Institute to Develop Stem Cell Therapies for Diseases of the Retina ReNeuron Group plc announced that it has signed a patent and know-how license agreement with Schepens Eye Research Institute regarding the Company’s ReN003 stem cell therapy program focused on diseases of the retina. [ReNeuron Group plc Press Release]
BioFocus Extends Collaboration with Usher III Initiative BioFocus announced that it has expanded a collaboration with the Usher III Initiative, Inc. [BioFocus Press Release] MIT and Skolkovo Foundation Announce Collaboration The Massachusetts Institute of Technology (MIT) and the Skolkovo Foundation announced the signing of a preliminary agreement to create the Skolkovo Institute of Science and Technology. [Massachusetts Institute of Technology Press Release]
Apeiron, CCRI and SIOPEN Join Forces Against Neuroblastoma Apeiron Biologics AG will support the clinical development of an immune therapy against high-risk neuroblastoma that is being conducted by the Children’s Cancer Research Institute (CCRI) and the European Neuroblastoma Research Network (SIOPEN). [Apeiron Biologics Press Release]
UC Davis Clinical and Translational Science Center Receives Renewed Grant Funding The University of California (UC) Davis Clinical and Translational Science Center received renewed grant funding of $20 million from the National Center for Research Resources. [University of California, Davis Press Release] University to Develop Skin Cancer Detection Tool to Save Lives De Montfort University, working in collaboration with the University Hospitals of Leicester NHS Trust’s Dermatology Department, has been awarded £75,000 to create a new device to help in the early detection of malignant melanoma skin cancer. [De Montfort University Press Release]
Children’s Hospital Los Angeles Researcher Wins Grant to Study Stem Cells’ Ability to Reverse Renal Fibrosis Laura Perin, PhD, co-director of Research in the division of Pediatric Urology at Children’s Hospital Los Angeles, has been awarded a $100,000 grant from the Alport Syndrome Foundation for her novel study of amniotic fluid stem cells in reversing the fibrosis common to inherited kidney disorder. [Children’s Hospital Los Angeles Press Release]
Gene Therapy Faces Setback as EU Rebuffs AMT Drug A novel gene therapy drug from Amsterdam Molecular Therapeutics (AMT) has been rejected by European regulators, underscoring the difficulty of getting gene-based treatments to market. [Reuters Press Release] Korea Is First to Approve Therapy A Korean pharmaceutical company took a step closer to beginning commercial production of the world’s first stem cell therapy as the Korea Food and Drug Administration said the approval will be given. [Korea JoonAng Daily Press Release] Fibrocell Science, Inc. Announces FDA Approval for laVÃv® (azficel-T) Fibrocell Science, Inc. announced that the U.S. Food and Drug Administration (FDA) approved the Company’s Biologics License Application for its lead product, laVÃv® (azficel-T). [Fibrocell Science, Inc. Press Release] Threshold Pharmaceuticals Announces Completion of Patient Recruitment for Phase II TH-302 Pancreatic Cancer Study Threshold Pharmaceuticals, Inc. announced the completion of patient enrollment into the Company’s Phase II pancreatic cancer study with TH-302, a novel small molecule tumor selective Hypoxia-Activated Prodrug that specifically targets tumor hypoxia and is applicable to a broad range of solid tumors. [Threshold Pharmaceuticals, Inc. Press Release]
Clavis Pharma Announces the Expansion by its Partner Clovis Oncology of the Observational Study to Determine Patient Stratification in its Pivotal LEAP Clinical Trial with CP-4126 Clavis Pharma ASA announces that Clovis Oncology, Inc, its development partner for CP-4126, has expanded the ongoing observational study to determine the patient stratification parameters in the pivotal LEAP clinical trial with CP-4126. [Clavis Pharma ASA Press Release] CEL-SCI Announces Start of Multikine Phase III Study by Orient Europharma in Taiwan CEL-SCI Corporation announced that its Taiwanese partner, Orient Europharma, has concluded the Site Initiation Visit for the first Taiwanese clinical center in CEL-SCI’s Phase III clinical trial for Multikine®, the Company’s flagship cancer immunotherapy. [Cel-Sci Corporation Press Release] Bergen County Spine Clinic Spine & Joint Center Offers New Stem Cell Treatment Options for Chronic Joint Problems A spine clinic Bergen County is now offering a revolutionary treatment for individuals with chronic joint problems using the patient’s own stem cells. Performed at Spine & Joint Center, the treatment utilizes adult stem cells harvested from the patient’s own fat cells, which are then injected into the injured joint to help stimulate the regeneration of healthy tissue. [PR Newswire Press Release] Stowers Institute Recruits Top Scientists in Developmental and Regenerative Biology Tatjana Piotrowski, Ph.D., and Alejandro Sánchez Alvarado, Ph.D., joined the Stowers Institute for Medical Research. [Stowers Institute for Medical Research Press Release] Aastrom Establishes Independent Steering Committee for REVIVE Phase III CLI Clinical Program Aastrom Biosciences, Inc. announced the formation of an independent steering committee to support the REVIVE Phase III clinical program for ixmyelocel-T. [Aastrom Biosciences, Inc. Press Release] Two Hutchinson Center Researchers Receive Prestigious Awards from Damon Runyon Cancer Research Foundation Two Fred Hutchinson Cancer Research Center researchers have received prestigious awards from the Damon Runyon Cancer Research Foundation. [Fred Hutchinson Cancer Research Center Press Release] Leaders in Fight Against Cancer Join Historic Initiative Addressing Clinical Investigator Shortage The Damon Runyon Cancer Research Foundation announced the formation of Accelerating Cancer Cures, a historic collaboration of the biopharmaceutical industry and academia with a strong commitment to achieving key breakthroughs in cancer treatments. [Damon Runyon Cancer Research Foundation Press Release] Sanofi Pasteur Opens $100M R&D Centre in Canada On June 22, Ontario Premier, Dalton McGuinty joined Mark Lievonen, President, Sanofi Pasteur Canada, to open a $101 million dollar vaccine research and development facility at Sanofi Pasteur’s Connaught Campus in north Toronto. [Sanofi Pasteur Press Release] |